RecombiMab anti-mouse c-Kit (CD117)

About RecombiMab anti-mouse c-Kit (CD117)

The 2B8-CP070 monoclonal antibody is a recombinant, chimeric version of the original 2B8 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG2b, κ to Mouse IgG2a, κ for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions—including Fc receptor binding and complement activation—and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The 2B8 monoclonal antibody reacts with mouse c-Kit also known as CD117, Steel factor receptor, stem cell factor receptor, and mast cell growth factor. c-Kit is a 145 kDa transmembrane tyrosine kinase and an immunoglobulin superfamily member. c-Kit is expressed on hematopoietic progenitor cells, mast cells, and acute myeloid leukemia (AML) cells and is a critical hematopoietic stem and progenitor cell receptor for the cytokine stem cell factor (SCF). The interaction of the c-Kit receptor and SCF promotes the proliferation and differentiation of hematopoietic progenitor cells. Studies have demonstrated that when 2B8 is conjugated to a cytotoxic compound, the antibody-drug conjugate (ADC) potently depleted greater than 99% of hematopoietic stem cells (HSCs) in-vivo and enabled the successful engraftment of donor hematopoietic cells without resulting in neutropenia or lymphopenia. The 2B8-ADC was more efficiently internalized by EML cells and more effective at depleting immunophenotypic and functional HSCs in vivo than murine anti-c-Kit clones 3C11 or ACK2.